Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta

Abstract

Compounds that inhibit P13Kδ activity, including compounds that selectively inhibit P13Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13Kδ plays a role in leukocyte function, using the compounds also are disclosed.

The invention claimed is: 
     
       1. A method of inhibiting a growth or a proliferation of cancer cells of hematopoietic origin comprising contacting the cancer cells with an effective amount of a compound, wherein said compound is 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
       2. The method of  claim 1 , wherein the cancer of hematopoietic origin is cells are lymphoma, leukemia, or multiple myeloma cells. 
     
     
       3. The method of  claim 2 , wherein the compound or the pharmaceutically acceptable salt thereof is the S-enantiomer. 
     
     
       4. A method of treating a condition in a subject, wherein the condition is lymphoma, leukemia or multiple myeloma, comprising administering to the subject an effective amount of a compound, wherein the compound is 5-fluoro-3-phenyl-2-[1-(9H-purin-6 -ylamino)-propyl]-3H-quinazolin-4-one 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
       5. The method of  claim 4 , wherein the condition is selected from the group consisting of Burkitt's lymphoma, Hodgkins' lymphoma, non-Hodgkins lymphoma, lymphocytic lymphoma, lymphocytic leukemia, multiple myeloma and chronic myeloid leukemia. 
     
     
       6. The method of  claim 4 , wherein the compound or the pharmaceutically acceptable salt thereof is the S-enantiomer.